Selected article for: "accumulation prevent and low density"

Author: Leclercq, Loïc
Title: Interactions between cyclodextrins and cellular components: Towards greener medical applications?
  • Document date: 2016_12_7
  • ID: 16pzlvzz_57
    Snippet: It is noteworthy that high concentrations of modified β-CDs result in rates of cell cholesterol efflux far in excess of those achieved with physiological cholesterol acceptors such as highdensity lipoproteins (HDL). Indeed, plasma levels of HDL are inversely associated with cardiovascular morbidity and mortality because this lipoprotein is responsible for transporting cholesterol to the liver where it can be eliminated [128] . The opposite holds.....
    Document: It is noteworthy that high concentrations of modified β-CDs result in rates of cell cholesterol efflux far in excess of those achieved with physiological cholesterol acceptors such as highdensity lipoproteins (HDL). Indeed, plasma levels of HDL are inversely associated with cardiovascular morbidity and mortality because this lipoprotein is responsible for transporting cholesterol to the liver where it can be eliminated [128] . The opposite holds for low-density lipoproteins (LDL). Their function is to transport cholesterol, free or esterified, in the blood and through the body to bring them to the cells. HDL particles also reduce macrophage accumulation, and thus help prevent or even regress atherosclerosis. The alteration of cellular cholesterol regulation, named the reverse cholesterol transport, RCT, could be used to block atheroprogression associated with different severity degrees of atherosclerosis pathogenesis. From the pioneering works of Irie et al., it became clear that CDs can be useful to prevent atherosclerosis [115, 129] .

    Search related documents:
    Co phrase search for related documents
    • atherosclerosis pathogenesis and cholesterol transport: 1, 2
    • atherosclerosis pathogenesis and LDL low density lipoprotein: 1
    • atherosclerosis pathogenesis and low density: 1
    • atherosclerosis pathogenesis and low density lipoprotein: 1
    • atherosclerosis pathogenesis and mortality cardiovascular morbidity: 1
    • atherosclerosis pathogenesis and reverse cholesterol transport: 1
    • cardiovascular morbidity and LDL low density lipoprotein: 1, 2, 3
    • cardiovascular morbidity and low density: 1, 2, 3, 4
    • cardiovascular morbidity and low density lipoprotein: 1, 2, 3, 4
    • cardiovascular morbidity and mortality cardiovascular morbidity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73